The Roles of Versican V1 and V2 Isoforms in Cell Proliferation and Apoptosis
-
Published:2005-03
Issue:3
Volume:16
Page:1330-1340
-
ISSN:1059-1524
-
Container-title:Molecular Biology of the Cell
-
language:en
-
Short-container-title:MBoC
Author:
Sheng Wang12, Wang Guizhi12, Wang Yelina12, Liang Jiyong13, Wen Jianping1, Zheng Peng-Sheng12, Wu Yaojiong12, Lee Vivian12, Slingerland Joyce13, Dumont Dan13, Yang Burton B.12
Affiliation:
1. Sunnybrook & Women's College Health Sciences Centre, Toronto, Ontario M4N 3M5, Canada 2. Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario M5S 1A1, Canada 3. Department of Medical Biophysics, University of Toronto, Ontario M5S 1A1, Canada
Abstract
Versican is a large chondroitin sulfate proteoglycan belonging to the lectican family. Alternative splicing of versican generates at least four isoforms named V0, V1, V2, and V3. We have shown that the versican V1 isoform not only enhanced cell proliferation, but also modulated cell cycle progression and protected the cells from apoptosis. Futhermore, the V1 isoform was able to not only activate proto-oncogene EGFR expression and modulate its downstream signaling pathway, but also induce p27 degradation and enhance CDK2 kinase activity. As well, the V1 isoform down-regulated the expression of the proapoptotic protein Bad. By contrast, the V2 isoform exhibited opposite biological activities by inhibiting cell proliferation and down-regulated the expression of EGFR and cyclin A. Furthermore, V2 did not contribute apoptotic resistance to the cells. In light of these results, we are reporting opposite functions for the two versican isoforms whose expression is differentially regulated. Our studies suggest that the roles of these two isoforms are associated with the subdomains CSβ and CSα, respectively. These results were confirmed by silencing the expression of versican V1 with small interfering RNA (siRNA), which abolished V1-enhanced cell proliferation and V1-induced reduction of apoptosis.
Publisher
American Society for Cell Biology (ASCB)
Subject
Cell Biology,Molecular Biology
Reference38 articles.
1. Ang, L. C., Zhang, Y., Cao, L., Yang, B. L., Young, B., Kiani, C., Lee, V., Allan, K., and Yang, B. B. (1999). Versican enhances locomotion of astrocytoma cells and reduces cell adhesion through its G1 domain.J. Neuropathol. Exp. Neurol.58, 597-605. 2. Blain, S. W., Scher, H. I., Cordon-Cardo, C., and Koff, A. (2003). p27 as a target for cancer therapeutics.Cancer Cell3, 111-115. 3. Carrano, A. C., Eytan, E., Hershko, A., and Pagano, M. (1999). SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27.Nat. Cell Biol.1, 193-199. 4. Cattaruzza, S., Schiappacassi, M., Kimata, K., Colombatti, A., and Perris, R. (2004). The globular domains of PG-M/versican modulate the proliferation-apoptosis equilibrium and invasive capabilities of tumor cells.FASEB J.18, 779-781. 5. Cattaruzza, S., Schiappacassi, M., Ljungberg-Rose, A., Spessotto, P., Perissinotto, D., Morgelin, M., Mucignat, M. T., Colombatti, A., and Perris, R. (2002). Distribution of PG-M/versican variants in human tissues and de novo expression of isoform V3 upon endothelial cell activation, migration, and neoangiogenesis in vitro.J. Biol. Chem.277, 47626-47635.
Cited by
140 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|